Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML5NF6)

Drug Name

4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol Drug Info

Synonyms

4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol; 945376-95-4; CHEMBL1269227; AK-87708; SCHEMBL2813127; CTK8B8546; DTXSID20680661; MolPort-023-331-308; XBHIAJWNXVJSAA-UHFFFAOYSA-N; KS-00000P8Z; ZINC64512573; ANW-60649; 6223AC; AKOS016003310; ACN-048482; QC-10378; DS-18362; ST2405344; KB-237849; AX8219172; AB0098071; DB-079951; TC-149394; AJ-114863; 4CH-017501

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 52947893
CAS Number: CAS 945376-95-4
TTD Drug ID: DML5NF6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting AMP-activated protein kinase (AMPK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acadesine	DM1RMF5	Diabetic complication	5A2Y	Phase 3	[2]
MB-11055	DM3RBJW	Fatty liver disease	DB92.Z	Phase 2	[3]
Imeglimin	DMMQFG2	Diabetic complication	5A2Y	Phase 2	[4]
PXL-770	DMNSRY7	Non-alcoholic fatty liver disease	DB92	Phase 2	[5]
ENERGI-F701	DMMIHSO	Alopecia	ED70	Phase 2	[6]
O-304	DMXM34I	Type 2 diabetes	5A11	Phase 2	[7]
IM156	DM4MY9C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Phenformin	DMQ52JG	Diabetic complication	5A2Y	Withdrawn from market	[9]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[10]
PMID23639540C13a	DMLXOAQ	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
AMP-activated protein kinase (AMPK)	TTLAFZV	AAPK1_HUMAN; AAKB1_HUMAN; AAKG1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular a... Bioorg Med Chem Lett. 2010 Nov 15;20(22):6394-9.
2	Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
3	Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
5	Clinical pipeline report, company report or official report of Poxel SA.
6	Clinical pipeline report, company report or official report of Energenesis Biomedical.
7	Clinical pipeline report, company report or official report of Betagenon.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.
10	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
11	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.